Searching for your content...
In-Language News
Contact Us
888-776-0942 from 8 AM - 10 PM ET
WuXi AppTec, a leading global provider of R&D and manufacturing enabling services in the pharmaceutical, biotechnology and medical device industries, ...
ViGeneron, a gene therapy company, and WuXi Advanced Therapies Inc. (WuXi ATU), a leading Contract, Testing, Development and Manufacturing...
WuXi Advanced Therapies Inc. (WuXi ATU) – a business unit of WuXi AppTec offering end-to-end contract services for the cell and gene therapies...
WuXi Advanced Therapies Inc. (WuXi ATU) today announced the expansion of its Cell & Gene Therapy Platforms with capabilities to provide high-quality...
Revenue Growth Accelerated to 35.4% Year-Over-Year to RMB 4,583 Million Adjusted Non-IFRS Net Profit Attributable to Owners of the Company Up 44.3%...
WuXi AppTec Second-Quarter 2020 Results Revenue Up 29.4% YoY to RMB4,044 Million Net Profit Attributable to Owners of the Company Up 111.0% YoY to...
WuXi AppTec is pleased to announce that they are about to launch the second session of the webinar series "Collaborations That Transform,"...
WuXi AppTec, a leading global pharmaceutical and medical device open-access capability and technology platform company, announced today the...
WuXi Advanced Therapies, a leading global Contract Development and Manufacturing Organization (CDMO) offering end-to-end contract services for the...
WuXi AppTec Co., Ltd. (stock code: 603259.SH / 2359.HK), a company that provides a broad portfolio of R&D and manufacturing services that enable...
WuXi AppTec announced today that the company's Wuhan site has resumed operations, in compliance with local regulations and global COVID-19 health and ...
With the end of the extended Lunar New Year holiday, WuXi AppTec sites in China have resumed operations today, with the exception of our site in...
STA Pharmaceutical Co., Ltd., (WuXi STA) – a subsidiary of WuXi AppTec – today announced the opening of its large-scale oligonucleotide active...
WuXi ATU Co., Ltd., (WuXi ATU) - a subsidiary of WuXi AppTec, and GeneMedicine - a South Korea-based gene therapy biotechnology company, have formed...
WuXi AppTec, a leading global provider of R&D and manufacturing services enabling companies in the pharmaceutical, biotechnology and medical device...
WuXi AppTec announced today that it has received investment grade corporate credit ratings from three global rating agencies: Moody's (Baa3), S&P...
STA Pharmaceutical Co., Ltd., (WuXi STA) – a subsidiary of WuXi AppTec – announced today that its Jinshan manufacturing facility in Shanghai, China...
WuXi AppTec Research Service Division and BioSolveIT today launched a new virtual chemical space called GalaXi®. Largely built from WuXi AppTec's...
WuXi AppTec today announced its launch of DELight, a novel DNA Encoded Library (DEL) service package, providing cost-effective and efficient hit...
WuXi AppTec Co., Ltd. (stock code: 603259.SH / 2359.HK), a platform that provides a broad portfolio of R&D and manufacturing services that enable...
Join PR Newswire for Journalists to access all of the free services designated to make your job easier.
In need of subject matter experts for your story? Submit a free ProfNet request and find the sources you need.